Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Albany Molecular Rebrands as AMRI

May 7, 2007 | A version of this story appeared in Volume 85, Issue 19

Albany Molecular Research Inc., the Albany, N.Y.-based contract pharmaceutical services firm, is rebranding itself as AMRI. CEO Thomas E. D'Ambra says the move reflects the company's "evolution from a small regional operation to a much larger business on a global scale." In recent years, AMRI has acquired or set up operations in Singapore, India, and Hungary. Separately, the company says it will lead the CancerGrid Project, a three-year research program funded by the European Commission in which 10 life sciences companies and academic centers will use grid-based computing technology to design chemical libraries. Their goal is to discover and develop anticancer agents.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.